Head to head

Excel HR vs Splendor X (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: Catalog new-price ranges: Excel HR, $95k–$135k; Splendor X, $130k–$165k. Check the source notes and request current quotes.
Practice fit: Both are listed under dual-wavelength laser. Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Dual-wavelength laser

View full device profile →

Device B

Dual-wavelength laser

View full device profile →

Price comparison

Price comparison: Cutera Excel HR vs Lumenis Splendor X
Attribute	Cutera Excel HR	Lumenis Splendor X
New price range	$95k–$135kSource not documented	$130k–$165kSource not documented
Used asking range	$40k–$70kSource not documented	$70k–$110kSource not documented
Payback calculator	View ROI calculator	View ROI calculator
Next step

New price range

Cutera Excel HR: $95k–$135kSource not documented
Lumenis Splendor X: $130k–$165kSource not documented

Used asking range

Cutera Excel HR: $40k–$70kSource not documented
Lumenis Splendor X: $70k–$110kSource not documented

Payback calculator

Cutera Excel HR: View ROI calculator
Lumenis Splendor X: View ROI calculator

Next step

Cutera Excel HR

Lumenis Splendor X

Consumable economics

Consumable economics: Cutera Excel HR vs Lumenis Splendor X
Attribute	Cutera Excel HR	Lumenis Splendor X
Consumable cost / lock-in	Supply pricing is not documented with a dated source yet. Request an itemized supply quote.	No per-treatment disposable. The recurring cost is wear parts — handpiece lenses, flashlamp, protective windows, ceramic reflector, Nd:YAG and alexandrite rods, fibre window. Not published — Lumenis does not publish US wear-part pricing and the figures previously shown carried no dated source.
Service cost	Not published	Not published

Consumable cost / lock-in

Cutera Excel HR: Supply pricing is not documented with a dated source yet. Request an itemized supply quote.
Lumenis Splendor X: No per-treatment disposable. The recurring cost is wear parts — handpiece lenses, flashlamp, protective windows, ceramic reflector, Nd:YAG and alexandrite rods, fibre window. Not published — Lumenis does not publish US wear-part pricing and the figures previously shown carried no dated source.

Service cost

Cutera Excel HR: Not published
Lumenis Splendor X: Not published

FDA clearance

FDA clearance: Cutera Excel HR vs Lumenis Splendor X
Attribute	Cutera Excel HR	Lumenis Splendor X
FDA status & indication	FDA ClearedK132185 Read FDA indication wording “Family of CoolGlide Aesthetic Lasers The Cutera Family of CoolGlide Aesthetic Lasers is intended for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. 755 nm: The Family of CoolGlide Aesthetic Lasers is indicated for temporary and permanent hair reduction on all skin types (Fitzpatrick I-VI), including tanned skin. Permanent hair reduction is defined as tong-term, stable reduction in hair counts observed atS6, 9,and 12 months after the end of a treatment regime. The Family of CoolGlide Aesthetic Lasers is also indicated for: o treatment of benign pigmented lesions o treatment of wrinkles ol photocoagulation of dermatological vascular lesions such as, but not limited to, port wine stains, hemangiomas and telangiectasias 1064 nm: Dermatology: The Family of CoolGlide Aesthetic Lasers is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasias, rossosa, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as, but not limited to, warts, scars, striae and psoriasis. The lasers are also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age soots), solar lentigos (sun spots), caf4 au lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue/black tattoos) and plaques. Additionally, the lasers are indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.”	FDA ClearedK241407, K243445 Read FDA indication wording “The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots), cafe au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and/or yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).”

FDA status & indication

Cutera Excel HR: FDA ClearedK132185
Read FDA indication wording
“Family of CoolGlide Aesthetic Lasers The Cutera Family of CoolGlide Aesthetic Lasers is intended for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. 755 nm: The Family of CoolGlide Aesthetic Lasers is indicated for temporary and permanent hair reduction on all skin types (Fitzpatrick I-VI), including tanned skin. Permanent hair reduction is defined as tong-term, stable reduction in hair counts observed atS6, 9,and 12 months after the end of a treatment regime. The Family of CoolGlide Aesthetic Lasers is also indicated for: o treatment of benign pigmented lesions o treatment of wrinkles ol photocoagulation of dermatological vascular lesions such as, but not limited to, port wine stains, hemangiomas and telangiectasias 1064 nm: Dermatology: The Family of CoolGlide Aesthetic Lasers is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasias, rossosa, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as, but not limited to, warts, scars, striae and psoriasis. The lasers are also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age soots), solar lentigos (sun spots), caf4 au lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue/black tattoos) and plaques. Additionally, the lasers are indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.”
Lumenis Splendor X: FDA ClearedK241407, K243445
Read FDA indication wording
“The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots), cafe au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and/or yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).”

Which chains run each

Which chains run each: Cutera Excel HR vs Lumenis Splendor X
Attribute	Cutera Excel HR	Lumenis Splendor X
Chain adoption	0 recorded pairings	0 recorded pairings
Chains using it	—	—
Approved reviews	0	0

Chain adoption

Cutera Excel HR: 0 recorded pairings
Lumenis Splendor X: 0 recorded pairings

Chains using it

Cutera Excel HR: —
Lumenis Splendor X: —

Approved reviews

Cutera Excel HR: 0
Lumenis Splendor X: 0

Specs and platform

Specs and platform: Cutera Excel HR vs Lumenis Splendor X
Attribute	Cutera Excel HR	Lumenis Splendor X
Manufacturer	Cutera	Lumenis
Built by (OEM)	Cutera Inc.	Lumenis Be Ltd.
Category	Dual-wavelength laser	Dual-wavelength laser
Technology	755nm alex + 1064nm Nd:YAG (Nd:YAG)	755+1064nm BLEND X square spot
Launch year	2015	2018
Status	Current	Current
Manufacturer source record	No linked source on file.	No linked source on file.

Manufacturer

Cutera Excel HR: Cutera
Lumenis Splendor X: Lumenis

Built by (OEM)

Cutera Excel HR: Cutera Inc.
Lumenis Splendor X: Lumenis Be Ltd.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

Lutronic Clarity II

Dual-wavelength laser

New: $100k–$140k

Quanta System Thunder (MT)

Dual-wavelength laser

New: $110k–$150k

Quanta System Duetto MT / MT Evo

Dual-wavelength laser

New: $80k–$120k

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.